Video

Newly Diagnosed Myeloma | Rebecca Silbermann, MD

Posted by
HealthTree Logo HealthTree
• November 23, 2026

Description

In this presentation from the HealthTree Portland Myeloma Roundtable (November 7, 2026), Rebecca Silbermann, MD, MMS of OHSU Knight Cancer Institute discusses how to protect bone health and proactively manage common multiple myeloma treatment side effects.

Key topics covered in this session:

• Understanding myeloma bone disease, bone-strengthening therapies, and fracture prevention

• Identifying and managing treatment-related side effects to maintain daily comfort and safety

• Partnering with your myeloma care team to adjust dosing and supportive care early

Timestamps:

0:00 Welcome & Introduction

2:16 Goals of Myeloma Treatment

3:06 Myeloma Survival Progress

4:52 Induction, Consolidation & Maintenance

6:36 Quad Therapy Induction

8:25 Consolidation & Stem Cell Transplant

9:25 Maintenance Therapy

10:27 Monitoring Disease Response Labs

14:45 Understanding MRD Testing

20:05 Myeloma Bone Health

24:21 Managing Treatment Side Effects

27:18 Exercise & Fatigue

Event details: https://healthtree.org/events/portlandrt2026

Transcript

HealthTree is a really remarkable organization, and I really appreciate that. Portland is now on the map for their work here. I have done some of their programs in Seattle and have always been really surprised to see my own patients and folks from Vancouver that have made the trek up through the traffic to come and be part of HealthTree work. So really, I am glad that we're all here today. I have the relatively easy job of getting us started in talking about newly diagnosed myeloma, and I know that there are people in this room who have been living with myeloma for quite some time. I'm hopeful that a lot of this is review, but I try to tell patients that I want them to feel comfortable realizing that they may not remember what they were told during the first four, five, several visits that they might have had with someone. So I think it's good to go over the basics again. I sometimes talk too fast, so if that's happening, let me know and I will do my best with the timer that we have. So we're going to talk about frontline treatment. I am not making this a heavy conversation about lots of trials, specifics about drugs. I want to talk about broad themes of treatment goals, how we monitor disease response, and then to talk about measurable or minimal residual disease, which is the thing that everybody seems to want to talk about all the time in myeloma these days, the last part of the talk is going to be about maintaining quality of life through treatment. And perhaps after someone has completed treatment, we're going to talk specifically about bone health. We're going to talk about side effect management. There's a lot of information on the slides, and I'm actually not sure if you'll have access to the slides afterwards. I think you probably will because HealthTree is good about that. I'm not going to read them all. We're just going to try to move through the general ideas. So when I think about the goal of myeloma treatment, number one is to improve symptoms that someone might have as a result of myeloma. Number two is the biggie. It's prevent myeloma from being the thing that shortens a person's life while allowing them to maintain their quality of life. So trying to find the really good balance point. And that's going to be different for every individual. It's also going to potentially change over the course of a person's treatment. And three is to allow each individual person to achieve the deepest and most durable disease response possible. That sometimes can look like prolonged periods of time of MRD negativity, the deepest remission that we can get for some other people that may not look the same and that may be acceptable for that individual person. We've made a lot of progress in myeloma, and I find this slide really encouraging. And I can absolutely imagine that as a patient or as a caregiver, this slide is still absolutely terrifying. We as myeloma doctors are excited because we can say that the five-year relative survival is over 60%. But as somebody on the other side of the room, that's still a pretty frightening number. And what I try to tell people is that this is data that has to be compiled over a long period of time, and it does not reflect the reality of every individual with a myeloma diagnosis that is being made in 2026, 2025, 2024, whenever it might have occurred, younger, fit, or whatever you want to say. That means standard risk patients now often have an overall survival of more than ten years, and that's actually an underestimate in my opinion. Part of what's interesting about this slide are the boxes that I've put in, which indicate when some of the big changes in myeloma treatment occurred. We talk about the modern age of myeloma therapy, as when proteasome inhibitors, bortezomib, and immunomodulatory lenalidomide were first introduced. I graduated med school right in between the approval of bortezomib and the approval of lenalidomide. I didn't know that I was going to do anything with myeloma, but that's an indication of how long we've been living in this modern age of myeloma. And I think the slope of the graph really shows you how, even with that modern age, we are continuing to make really extraordinary progress in the management of this condition. We are taught as physicians that one of the first things you're supposed to do when you meet a myeloma patient is to decide, are they someone who we think is going to be transplant eligible, or are they someone who we think is going to be transplant ineligible? And then we're meant to frame our treatment plans based on that initial decision. We still talk about steps in myeloma treatment using that framework, but that is one of the biggest things that has changed recently. So we talk about the initial treatment as induction treatment, which essentially means getting rid of as many myeloma cells as efficiently as you can without making the person feel like garbage. Then we talk about some kind of consolidation therapy, which is hopefully going to allow people to maintain and hold their best disease response for as long as possible. And then we talk about a lightning of therapy, which is what we call maintenance therapy. The green box here, the managing relapse box, is one that I change in most of the slides that I make when I'm speaking to physicians or other healthcare practitioners, because managing relapse has become a multi-step process for patients with myeloma. And we're going to be hearing about that later on in the presentation. It used to be that we would tell people that their first remission was likely going to be the deepest and most durable remission that they would enjoy as a myeloma patient. We found that our newer drugs are actually even better than the initial drugs that we give patients. And so people can achieve very, very deep disease remissions after they've already relapsed once, sometimes twice, sometimes more than that. For most patients in 2026. I think that induction therapies should include what we call quad therapy or four drugs at once. That is something that is a little bit controversial and something that is evolving. We used to say that people who were less fit, so people who we didn't think were likely to go on to have stem cell transplant might not be strong enough, or might not be able to handle receiving all of the initial myeloma drugs at one time. And what we've learned is that if you are careful, if you're being watched, if you're able to have ongoing conversations with your care team, we really can get most patients through this initial set of treatments and get them through it pretty well. There have been sets of studies that have looked at the impact of reducing doses of medicines, particularly everybody's favorite, the dexamethasone. And what they've really shown is that if you pull back on the dexamethasone dosing, you can keep people on treatment for longer in general, and you can still afford an excellent, excellent disease response. The four types of drugs that we're usually talking about include a proteasome proteasome inhibitor. So that sport or an immunomodulatory agent that's lenalidomide or Revlimid, a CD38 monoclonal antibody. That's daratumumab. And then our favorite the steroid. In some cases we really do choose to not give four drugs at once. That could be because somebody is extremely frail. It could be because somebody has a lot of other medical comorbidities going into this process. An example might be if they have really significant peripheral neuropathy, and we don't want to risk worsening that with bortezomib. And another example could be really severe cardiac disease. Second step of treatment is what we call consolidation. For some people this is stem cell transplant. And as many of you in this room know, that's the kind of transplant where you're giving your own cells back to yourself. For people who we feel are not appropriate for stem cell transplant or increasingly, people who don't want stem cell transplant, this can mean ongoing cycles of the induction therapy. So for example, the first set of therapies might take four cycles or about four months. If someone's not going to go on to transplant, we might give them another two three cycles. Try to really get that disease response solidified and down as far as we can. Clinical trials are actively investigating if transplant still provides a benefit in the current era of these modern therapies, we're doing combinations of treatment at once. Many of you have participated in these trials, and we really appreciate that. And we're hoping to keep the conversation going so that we can keep improving on therapies. And finally, maintenance therapy is something that myeloma doctors used to argue about a lot as to what is the definition of maintenance therapy? In my mind, maintenance therapy meant lighter therapy. It meant no dexamethasone. It meant hopefully a manageable therapy that would keep the disease under control while allowing a person to live the life that they have been wanting to live. We used to consistently talk about one drug at a time, often lenalidomide. Sometimes bortezomib. In my mind, this was always without steroids. We're increasingly using combination therapy dare team lenalidomide initially and then pulling back based on disease response. There have been recent articles in the medical literature that have hit the popular science literature about discontinuation of maintenance therapy entirely. There are clinical trials that have looked at this issue. It's something that is an open and very intriguing possibility that I think more and more of us are talking about. So moving on to monitoring disease response. This is hopefully a refresh for most people. But we get a lot of tubes of blood. When people come into the clinic, we're looking at a whole set of labs. And I think it makes sense to just read through what we're looking at. The Y-shaped situation in the middle is the schematic of the immunoglobulin protein. The red arms are the light chains. And the light chains are called kappa or lambda. And they can break off and they can be measured in the blood. On the other side of the slide, you see a figure that shows what the serum electrophoresis pattern looks like in the normal condition. I said I wasn't going to point, I'm going to try. This is the abnormal version of ours here. That's the M spike. That's the M spike that we are trying to measure and hopefully see come down. Some patients will have an M spike that's measurable in the blood. Someone will. Some will have an M spike that's measurable in the urine. Some will not have an M spike at all. They might instead have measurable abnormal kappa free light chains. And in that situation, we might be looking at the relative amount of light chain that's present. We try to look at the ratio of the kappa to lambda light chains, because you can see changes in the total kappa and total lambda numbers that can mimic a change in disease, but it can actually be because of changes in inflammatory state. So if someone has infection or something else going on, their kappa and lambda might both go up. And that isn't necessarily reflecting that the myeloma is changing. The heavy chain is the IG, the IGA, the IG, the IGD, the IG. In some cases, that is something that we may check depending on an individual's disease profile and sometimes can be used in conjunction with following the light chains in the M spike. When you're looking at your lab results, a couple things that I like to remind people of. The biggest is that the kappa and the lambda light chain units are different depending on where the blood is drawn. So at OHSU we represent the lab in the milligrams per liter unit. Other labs, including other labs in town represented as milligrams per deciliter. And that's a decimal point change. And that can cause a lot of worry if someone doesn't recognize that. That is the reason that the numbers might be markedly different. So I think it's important to talk to your care team, figure out what labs they are using when they're assessing whether your disease response is appropriate, is what they're expecting to see. Ask how often they are checking the labs. The proteins only hang out in the blood for a certain period of time. The monoclonal protein is present for about a month, and so it doesn't always make sense to check the labs too often when someone's beginning therapy, if we're feeling a little bit anxious about how they're doing and they have a measurable light chain component, we might check the light chains more frequently because those are cleared faster in the body, and we might see the effect of the treatment on the light chains more quickly. Test results can vary between labs. I preach this to all of my patients over and over and over again, so just be aware of that and understand that we can't always say that the labs drawn in Medford are going to be directly comparable to the labs drawn in Portland. Don't compare your labs to those of the person sitting next to you. And once myeloma is different, someone can be hanging out with an M protein of four and feeling fine, and someone might have a non-measurable M protein and have really significant disease side effects. And so it's really I think important to keep that in mind. And then the last point is one that comes up a lot. There's not a magic number that necessarily necessitates a treatment change for all people. It's really an individual conversation in the context of that individuals disease course. Okay. Measurable residual disease or MRD. We've talked about the labs. And the old analogy is that of an iceberg that there's all of this disease that is in the body, and we can only get a limited amount of information from the blood or urine tests. We use terms like complete response or complete remission, stringent complete remission. And those are old terms that rely on the M protein, the light chains and the bone marrow clearing. We now have more advanced technology that allows us to look deeper into the bone marrow, to assess whether there are still myeloma cells present at very, very small numbers. And that's where the term MRD comes in. So MRD refers to the small number of myeloma cells that may remain in the body during and after treatment. We use the term MRD positive or MRD detectable to indicate that you have more than one cell in 100,000 MRD negative is something that myeloma doctors argue about, but fewer than 1 in 100,000 or 1 in 1,000,000 cells, which is the lower limit of one of the tests that we commonly use. MRD negativity is good. It's better to have less myeloma in your body. Prolonged MRD negativity is also good. And in some cases, we are using MRD results to help inform what to do with an individual's treatment in myeloma. We are currently measuring MRD from the bone marrow. This is different from some other kinds of blood cancers where peripheral blood testing is being done. Blood testing for MRD is under active investigation. My opinion is that it's not quite ready for prime time. I think we're getting closer. But right now when I'm talking about an MRD test, I'm talking about a marrow assessment. There's two main ways of doing it right now. One is with a specialized type of flow cytometry. The old term was EuroFlow. But we can now send it to the Mayo Clinic. So that's not Europe. The second is next generation sequencing or the clonoSEQ test, where the samples are sent to a lab in in Seattle. So our center generally uses the testing. There's two parts to that testing. The first is that an ID sample needs to be sent. This is something that's sent from hopefully a sample that had a lot of myeloma on it. It acts as a barcode for your future testing. And then the future samples are going to refer back to that barcode to go looking for evidence of myeloma cells that may still still be present. Did I do that or did. Oh. Okay. The MRD report is something that people may have seen. I'm just going to go lightly through this. The way the report is structured, in the blue box at the top, they will give you a number. And certainly the number zero is good, but any low number is something that's encouraging and is something that will then hopefully feed conversation with your care team. At the bottom of the report, the company generates a line graph which tracks your results over time and allows you to see how the current testing compares with where you began. In many cases, we're seeing that the MRD is going down over time, but people have disease that becomes more active again, and then we might start to see that the MRD is going up. And that often warrants a conversation about what we're doing with that information, how we're looking at that information in the context of what might be seen in the blood tests or in the rest of the body. So common questions that I was thinking about when I was writing these slides. Can a person who is MRD positive after treatment still have good outcomes? Yes, absolutely. Yes. This is a new test. Some patients remain MRD positive. It's not something that we fully understand, but some of them seem to have ongoing MRD positivity for a long period of time. Number two can a person who is MRD positive become MRD negative? The answer to that is yes. We can see disease responses deepening over time, sometimes without changing therapy at all. So when we talk about that framework of induction consolidation maintenance, there are several studies that had paralleled data collected on MRD. And patients remained on the same treatment pathway. And we saw that after induction and then after consolidation and then throughout maintenance, the MRD response continued to deepen with time. And then the last one is the big one. And we'll talk about this in the breakout. Does MRD negativity equal cure? The answer is no, not yet. But it is part of the definition of cure that has been proposed. MRD negativity is also something that has been validated and approved by governing bodies to use an assessment of the efficacy of clinical trial results with new drug developments. All right. I got nine minutes and 30 seconds. So living well with myeloma, bone health, side effect management, exercise. Bone problems and myeloma are extremely common. Myeloma is the most frequent cancer to involve the bone. Up to 90% of myeloma patients develop bone problems during the course of their disease, about 70%. I think it's actually more have bone pain at the time of diagnosis, and myeloma could involve any bone of the body. Normally, we have a continuous coupled remodeling process where our body maintains its skeleton. We have these big cells that are called osteoclasts that take away bone mineral. We have these little guys called osteoblasts that lay down new mineral. And normally it's an even interaction bones being taken away, bones being laid down in myeloma. This is an uncoupled process. So I added these little purple egg yolk situation things which are the myeloma cells. They directly impact the activity of the bone cells. They increase the activity of the osteoclasts. They directly inhibit the osteoblasts which lay down the new mineral. And the result is that you have more bone loss than bone formation. So we treat myeloma bone disease by trying to recover that process, trying to shut down the bone resorption. The treatment goals are to prevent fracture, prevent new bone damage and bone loss, and to improve pain. We treat the myeloma component. We get rid of the myeloma cells themselves. And then we also try to treat those bone activating or bone forming cells themselves. So one piece that's not on the slide is that you want to control the disease. The other piece is that you want to use bisphosphonates, zoledronic acid or RANK ligand inhibitors, denosumab or Xgeva to try to inhibit the activity of those cells that are eating away at the bone. So zoledronic acid and denosumab can both decrease the risk of fracture. They unfortunately do not prevent all fractures in all patients. They also do not directly allow patients to heal their bone lesions, and we do have newer drugs that they are using, and they're getting more comfortable in using them to help actively build bone in patients. And so some of you I know work with the endocrinology team to receive those medications. Osteonecrosis of the jaw is a rare but very real potential side effect of these bone directed agents. What happens is that you have inflammation or irritation in the jaw bone, and you can have, an injury that occurs to the jaw that doesn't heal properly. So, we know that from the original studies on bone directed therapies, that this occurs in about 3% of patients receiving these agents. We also know that in the setting of hopefully regular dental care, this is generally preventable. So this is the reason that I'm always harping on people to go to their dentist, keep their cleanings up, use their dental floss, and to really let people know if they're noticing any change in their in their mouth. If someone has to have a routine dental procedure, that's fine. If they need to have an extraction or anything that a layperson doesn't fully understand what the dentist is talking about, I think that they should let our clinic know we will hold the doses of the bone directed therapy, and then we will resume when the dentist or the periodontist, or whomever it is says that it's okay to resume. We want to try to have as much space in between these doses to help keep the healing as normal as possible. What else can we do to maintain our bones? Adequate vitamin D is a challenge for everybody living north of the 37th parallel, so that includes us. About 40% of myeloma patients are D deficient. And I think that's a national number. I don't actually know the percentage of patients in Portland who are D deficient. Pretty sure it's quite high. And so vitamin D is required for most patients. We check vitamin D levels or we try to check them somewhat regularly. Calcium supplementation is also very important. And weight bearing exercise is also really a requirement to help maintain healthy, healthy bones. All right. Treatment side effects I'm going to fly through this stuff. Common things that I hear about are neuropathy, taste alterations and dry mouth skin changes and tiredness. The biggest thing is to talk to your team. We can't read your mind. Unfortunately or fortunately, we don't know what you're thinking. Please just tell us what you're what you're noticing and particularly tell us if you're noticing something that's different and that you're worried about. Because oftentimes we can give advice to try to help. There's many types of neuropathy that can mean painful numbness or tingling, but it can also mean balance changes. It can mean difficulty manipulating small objects. It can mean that you can't do the buttons on the cuff of your shirt. This can be related to treatment, and if we know about it we could adjust dosing sometimes will reduce dosing or spread out dosing. And we have medications that can help with symptoms. None of them are magic unfortunately. And some people do have a lot of side effects from the medications. They don't think that it's worth it. But I think it's worth talking about. Dry mouth and taste alterations can come from some drugs in particular. They could also come from transplant. Generally we advise that people increase hydration, do anything they can to try to increase salivation so tart foods can help. And then I really think people need to experiment with flavors and figure out what is manageable for them, recognizing that that's likely something that's going to change with time. We suggest that people try to avoid caffeine and alcohol because it could increase dryness, avoid smoking and chewing tobacco. But it is something that can be quite persistent and it seems to be very different amongst different people. Some people say that Revlimid has changed their sense of taste, and it never has gotten back to normal. Others don't seem to notice that at all. Skin rashes can be variable. Some of them are expected. We try to warn people that when they start Revlimid, they might develop skin rash, redness, or itching and that sometimes we can work through it. But even with that information, we still want to know about it because we want to assess how significant the symptoms are, where they are on the body, and help talk through the management of those symptoms. We're often talking about moisturizers. Sometimes we're talking about anti allergy medications. For some types of medications we're talking about topical steroids. And finally tiredness is tricky. It comes from myeloma on its own. And it can also come from treatment. We start off by reviewing your sleep reviewing your medications. And oftentimes we end up talking about lifestyle stuff. We talk about physical activity. We talk about how you're spending time. And there's again, not a magic answer for all people, but it's something that is important to acknowledge and important to try to try to improve if at all possible. So that gets us to exercise. This is the one figure that I have in this slide deck. And it's because I think it's quite lovely. This was a study that was done in 1999 of patients who were undergoing chemo and radiation, not myeloma patients, just patients. And they were self assessing their tiredness. Increased tiredness is up on the scale. Patients were enrolled in a home based walking program or not. And the people who were able to get some exercise, even walking for 15 or 30 minutes a day, had improvement in their assessment of their accumulation of fatigue through the course of treatment. That's really compelling, and I think it's something that we don't talk about enough. The immediate goal is to avoid inactivity. And I very much understand how it's easy to fall into the trap, really, of being inactive. You have this new diagnosis, you're getting all these medicines, you're getting your labs checked, and you're told that your bones are fragile. So of course you're going to be a little bit nervous about moving. But I think that we need to reframe that. We need to try to encourage people to get up, move around, do what they're able to do, perhaps keep track of their steps in a day and then try to increase it. It doesn't have to be dramatic. I'm not telling you to join a CrossFit gym, but I want people to think about this and try to move because it helps physically. It also helps mentally. Exercise prescriptions are something that we've been talking about in the medical community for decades, and I think we're doing a crummy job of actually doing them. One of the exercise physiologists who works at OHSU talks about light versus moderate exercise. And she defines moderate as something that you can do while still talking to your friend as you're going for a walk. But you couldn't sing on your walk. So if you could walk and chat, that's considered moderate exercise. And her recommendation is to start with doing that for up to 30 minutes a day, a few times a week and and see if you have an improvement. And I think that's something that's very doable. There are exercise associated programs for cancer patients that are in development and are increasing within the cancer center, and I'm hopeful that that'll be something that we can share with people moving forward. All right. Last thought that I wanted to leave you with, but that's really my last slide. So thank you very much. I really appreciate your time.